Cargando…
More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
A number of commentaries have been published over the past 4 years by the present author on the manifest flaws in the reference case value assessment framework of the Institute for Economic and Clinical Review. The recent release of the evidence report on sickle cell disease continues ICER’s commitm...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051927/ https://www.ncbi.nlm.nih.gov/pubmed/34007618 http://dx.doi.org/10.24926/iip.v11i2.3123 |
Ejemplares similares
-
More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
por: Langley, Paul C
Publicado: (2020) -
ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
por: Langley, Paul C
Publicado: (2019) -
Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022) -
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018) -
Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds
por: Langley, Paul C
Publicado: (2020)